Sildenafil improves clinical and functional status of an elderly postmenopausal female with ‘out of proportion’ PH associated with left heart disease

Case

A seventy-two years old woman, with arterial hypertension, diabetes mellitus, permanent atrial fibrillation and previous mitral commisuroplasty for rheumatic mitral stenosis, was admitted to our Department, after a new decompensated heart failure (WHO functional class III-IV).

An echocardiographic examination showed dilated right chambers, left ventricle with D-shaped configuration, moderate mitral stenosis (mean PG: 9 mmHg), moderate aortic regurgitation, severe tricuspid regurgitation and the continuous-wave Doppler showed a peak velocity consistent with a pressure gradient of 95 mmHg and a pulmonary arterial systolic pressure (PAsP) of 115 mmHg.

Right heart catheterization showed a high mean pulmonary arterial pressure (mPAP 80 mmHg) and high pulmonary arterial wedge pressure (PWP 30 mmHg) with transpulmonary gradient (TPG) >12 mmHg (mean PAP - mean PWP: 50 mmHg). She performed the six minutes walking test and walked 230 meters (53% of predicted value).

In ambulatory setting, the therapy for left heart failure was most titrated; however, she remained in WHO functional class III and she refused cardiac surgery evaluation. So, we started therapy with sildenafil 10 mg die (with slow titration up to 60 mg die). After one month of sildenafil therapy, she began to improve functional and clinical status (260 m at the 6MWT and WHO functional class II-III) with a reduction of the PAsP (95 mmHg). After four months of therapy, she received up to sildenafil 60 mg die and further functional status improved (WHO functional class II). After 6 months no major events (hospitalization, cardiac death, death) was observed.

Discussion

Pulmonary hypertension with elevated TPG occurs in patients with mitral stenosis, and is significantly more common in females [1].

Most of the advances in the treatment of PH have been made in PAH, while a few progress has been made for the PH due to left heart diseases. Despite the lack of data, drugs with proven efficacy in PAH are increasingly being used for other forms of PH.

Recent studies suggest the usefulness of sildenafil, a phosphodiesterase-5 inhibitor in particular subgroups. In fact, sildenafil appears to be well tolerated and can improve markers of cardiovascular and pulmonary function in patients with HF. So, the PDE5 inhibitors may be a therapeutic option for patients who cannot tolerate standard therapy for HF or who remain symptomatic with standard therapy, as in this case [2].

Sildenafil improves exercise capacity and quality of life in patients with systolic HF with secondary PH [3] and improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure [4].
However, contrast data come from subgroup with HFpEF. In fact, in a multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial with 216 stable outpatients with HFpEF, the authors showed administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status [5].

Instead, we report a case of an elderly post-menopausal female with residual mitral stenosis post-commissurotomy and permanent atrial fibrillation, where the therapy for left heart failure was most titrated, but, she remained in WHO functional class III. So, sildenafil therapy was performed and she began to improve functional and clinical status with a reduction of the PAsPs. After four months of therapy, she received up to sildenafil 60 mg die and further functional status improved (WHO functional class II).

Over the last decade there has been growing interest in using phosphodiesterase-5 (PDE-5) inhibitors in HF associated with group 2 pulmonary hypertension (PH), with benefits reported on pulmonary haemodynamic and functional status only in a single-centre trials [3], however our data seem to confirm it.

Further studies to assess sildenafil efficacy and tolerability in patients with HF and evidence of group 2 PH are necessary, so recently, a randomized, placebo-controlled multinational trial designed to assess this aim in patients with HF (WHO functional class II or III) and evidence of group 2 PH was designed and we looking forward the results [6].

Riassunto

Riportiamo il caso di una donna anziana con scompenso cardiaco a preservata frazione d’ie-